Résumé
Dendritic cells (DC) were initially described as antigen presenting cells able to prime naive T cells. In fact, dendritic cells are also able to activate natural killer (NK) cells. The crosstalk between DC and NK is now regarded as a main stage in the initiation of innate and adaptative immune responses. Moreover, DC mediated-NK cell activation is particularly efficient since DC promote both effector functions and survival or proliferation of NK cells. Furthermore, recent publications in the field of NK cell biology underscore a role for NK cells in anti-tumor effects. NK cell-based immunotherapy should be reconsidered. Here, we will report how pioneering immunotherapy trials based on natural cytotoxicity and progress in NK cell biology can promote NK cells in anti-tumor immune responses. Then, we will discuss the biological features of the DC/NK crosstalk and its implementations in immunotherapy protocols.
Titre traduit de la contribution | NK cell-based immunotherapy: New prospects and involvement of dendritic cells |
---|---|
langue originale | Français |
Pages (de - à) | 699-705 |
Nombre de pages | 7 |
journal | Bulletin du Cancer |
Volume | 90 |
Numéro de publication | 8-9 |
état | Publié - 1 août 2003 |
mots-clés
- Dendritic cell
- Immunotherapy
- NK cell